2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3388 Safety and efficacy of olverembatinib (HQP1351) and lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with venetoclax relapsed/refractory acute myeloid leukemia‌ (venetoclax R/R AML)

Xudong Wei, MD, PhD, Huafeng Wang, MD2, Jianyu Weng, MD, PhD3, Ruihua Mi, MD, PhD4, Yang Liang, MD, PhD5, Suning Chen, MD, PhD6, Hongbing Ma, MD, PhD7, Wenjuan He, PhD8, Chunkang Chang, MD, PhD9, Lihui Liu, PhD10, Lichuang Men, MSc11, Yan Xiong, PhD12, Fang Lu13, Danhua Cong, MS14, Dajun Yang, MD, PhD15, Yifan Zhai, MD, PhD16, Jie Jin, MD17
1 Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University,, Zhengzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Guangdong Provincial People’s Hospital, Guangzhou, China
4 Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University,, Zhengzhou, China
5 Sun Yat-sen University Cancer Center, Guangzhou, China
6 The First Affiliated Hospital of Soochow University, Suzhou, China
7 West China Hospital, Sichuan University, Chengdu, China
8 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Shanghai Sixth People’s Hospital, Shanghai, China
10 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
11 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
12 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
13 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
14 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
15 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
16 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
17 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background

Following the approval of B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax, several combination regimens demonstrated promising efficacy in AML. However, therapeutic options remain limited after venetoclax failure, and outcomes are poor. Olverembatinib, a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI), also targets kinases associated with leukemogenesis and venetoclax resistance, including FLT3, KIT, PDGFR, the Src family, PI3K, and FGFR. In preclinical venetoclax-resistant AML models, olverembatinib synergized with lisaftoclax and AZA to enhance antileukemic activity and overcome venetoclax resistance. In a phase 1b clinical trial, we are evaluating whether olverembatinib in combination with lisaftoclax can overcome venetoclax resistance in patients with BCL-2i-R/R AML.

Methods

Olverembatinib 30 or 40 mg was administered orally every other day (QOD) every 28 days (as a cycle) and lisaftoclax 600 mg was administered orally daily (QD) either on days 1-14 or days 1-28. A daily ramp-up schedule was used during the first cycle to prevent tumor lysis syndrome (TLS). AZA 75 mg/m2 or homoharringtonine (HHT) 2 mg QD was administered on days 1-7 in repeated 28-day cycles. The objectives were to assess pharmacokinetics, safety, and efficacy.

Results

As of July 23, 2026, a total of 33 patients with venetoclax or other BCL-2i treatment-failed R/R AML had been enrolled. The median (range) age was 67 (21-80) years and 42.4% of patients were male. Among them, 11 patients had relapsed disease after 2 lines of therapy, 11 patients had relapsed disease after >2 lines, 2 had AML refractory to prior BCL-2i plus AZA ± HHT, and 3 were refractory to BCL-2i plus AZA administered after relapse following intensive chemotherapy. Relapse after first-line BCL-2i plus AZA ± HHT occurred in 6 patients (venetoclax n=5, sonrotoclax n=1). Patients had received a median of 8 prior treatment cycles (range, 2-30). Among 28 patients with genotype data, 10 (35.7%) had ASXL1 mutations; 5 (17.9%), N/KRAS mutations; 5 (17.9%) IDH1/2 mutations; 4 (14.3%) with TP53 mutations; and 3 (10.7%) with FLT3-ITD mutations. A total of 87.9% of patients experienced treatment-emergent adverse events (TEAEs), including grade ≥3 AEs in 84.8% and serious AEs in 27.3%. Common (≥10% incidence) grade ≥3 nonhematologic TEAEs included pneumonia and hypokalemia (18.2% each). Common grade ≥3 hematologic TEAEs included leukocyte count decreased (57.6%), neutropenia (54.5%), febrile neutropenia (39.4%), thrombocytopenia (27.3%), and anemia (24.2%). Grade ≥3 infections were reported in 36.4% of patients and were treatment related in 21.2%. No TLS was reported. Thirty- and 60-day mortality rates were both 9.1%. In 20 evaluable patients treated with olverembatinib, lisaftoclax and AZA, the overall response rate (ORR; CR+ CRi, 15%; morphologic leukemia-free state [MLFS], 10%; PR, 5%) was 30% (95% CI, 11.9%-54.3%). In 6 evaluable patients treated with olverembatinib, lisaftoclax, and HHT, the ORR was 33.3%, with 1 CR and 1 MLFS. Furthermore, the CR + CRi rate was 40% in patients with AML that had relapsed after first-line BCL-2i + AZA or HHT; the CR + CRi rate was 19% in patients relapsing after 1 to 3 prior lines of treatment. Median overall survival from the onset of triplet therapy was 4.73 months (95% CI, 2.43-NR) in the olverembatinib, lisaftoclax, and AZA cohort, and 5.32 months (95% CI, 3.19-NR) in the olverembatinib, lisaftoclax, and HHT cohort.

Conclusions

Olverembatinib in combination with lisaftoclax were well tolerated and exhibited encouraging antileukemic activity in heavily pretreated patients with venetoclax or other BCL-2 inhibitor treatment failed AML. Activity appeared to be particularly promising in patients relapsing after frontline BCL-2i-based therapy. An acceptable safety profile and efficacy data support further clinical development of these combinations. Internal study identifier: APG2575AC101. ClinicalTrials.gov identifier: NCT04501120.

Xudong Wei, MD, PhD: No relevant conflicts of interest to declare.